We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
+0.13%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$460M
AUM Growth
+$34.8M
(+8.2%)
Cap. Flow
+$33.8M
Cap. Flow
% of AUM
7.34%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
42
New
9
Increased
17
Reduced
14
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$24.6M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$9.03M |
| 3 |
Zimmer Biomet
ZBH
|
+$7.81M |
| 4 |
AstraZeneca
AZN
|
+$7.44M |
| 5 |
Bruker
BRKR
|
+$6.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$13M |
| 2 |
Pfizer
PFE
|
+$8.08M |
| 3 |
Labcorp
LH
|
+$7.34M |
| 4 |
Cardinal Health
CAH
|
+$6.4M |
| 5 |
Boston Scientific
BSX
|
+$4.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$122B
| $6.46M | 1.4% |
24,758
-14,311
| -37% | -$3.4M |
|
27
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.15M | 1.34% |
79,759
-33,789
| -30% | -$2.83M |
|
|
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.95M | 1.07% |
+80,843
| New | +$4.2M |
|
29
Rigel Pharmaceuticals
RIGL
$692M
| $4.38M | 0.95% |
146,668
-292
| -0.2% | -$7.91K |
|
|
PDCO
30
DELISTED
Patterson Companies, Inc.
PDCO
| $4.2M | 0.91% |
129,757
+6,810
| +6% | +$202K |
|
|
SAGE
31
DELISTED
Sage Therapeutics
SAGE
| $3.92M | 0.85% |
118,476
+19,572
| +20% | +$736K |
|
32
Ultragenyx Pharmaceutical
RARE
$2.65B
| $3.36M | 0.73% |
+46,221
| New | +$3.22M |
|
33
PTC Therapeutics
PTCT
$6.29B
| $2.98M | 0.65% |
+79,864
| New | +$3.08M |
|
34
Novavax
NVAX
$1.23B
| $2.82M | 0.61% |
38,324
+24,978
| +187% | +$2.23M |
|
35
Dentsply Sirona
XRAY
$2.61B
| $2.73M | 0.59% |
55,516
-59,300
| -52% | -$3.13M |
|
36
Quanterix
QTRX
$173M
| $2.59M | 0.56% |
+88,670
| New | +$2.71M |
|
|
SLGC
37
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $2.42M | 0.53% |
+301,224
| New | +$2.66M |
|
38
Vir Biotechnology
VIR
$1.48B
| $2.06M | 0.45% |
80,223
+36,223
| +82% | +$1.07M |
|
39
Atara Biotherapeutics
ATRA
$69.5M
| $1.15M | 0.25% |
+4,949
| New | +$1.58M |
|
|
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $976K | 0.21% |
11,875
-14,231
| -55% | -$1.46M |
|
41
BioNTech
BNTX
$23B
| – | – |
-13,032
| Closed | -$3.36M |
|
|
42
Labcorp
LH
$24.7B
| – | – |
-27,211
| Closed | -$7.34M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q1 2022 Portfolio in Review
As of Q1 2022, Sector Gamma AS held 42 positions worth $460M, up 8.2% from $425M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sector Gamma AS deployed $33.8M of net new capital in Q1 2022, opening 9 new positions and adding to 17 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 59,251 shares worth $9.68M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Becton Dickinson, an estimated $13M trimmed.
- Sector Gamma AS's largest Q1 2022 buy was Alnylam Pharmaceuticals: 59,251 shares worth $9.68M.
- Sector Gamma AS added most to Gilead Sciences in Q1 2022, an estimated $24.6M increase.
- Sector Gamma AS's biggest Q1 2022 reduction was Becton Dickinson, cutting an estimated $13M.
- Sector Gamma AS fully exited Labcorp in Q1 2022, selling an estimated $7.34M.
- Sector Gamma AS's ten largest holdings make up 56% of its $460M portfolio in Q1 2022.
- Sector Gamma AS opened 9 new positions and closed 2 in Q1 2022.
- Sector Gamma AS's portfolio value rose 8.2% quarter-over-quarter to $460M.
Based on Sector Gamma AS's 13F filing for Q1 2022, filed 6 May 2022.